Terms: = Endocrine gland cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Treatment
223 results:
1. Armored TGFβRIIDN ROR1-car T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
[TBL] [Abstract] [Full Text] [Related]
2. Efficient car T cell targeting of the CA125 extracellular repeat domain of MUC16.
Casey NP; Kleinmanns K; Forcados C; Gelebart PF; Joaquina S; Lode M; Benard E; Kaveh F; Caulier B; Helgestad Gjerde C; García de Jalón E; Warren DJ; Lindemann K; Rokkones E; Davidson B; Myhre MR; Kvalheim G; Bjørge L; McCormack E; Inderberg EM; Wälchli S
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604812
[TBL] [Abstract] [Full Text] [Related]
3. Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted car-T cell therapy: a case report.
Zhong G; Zhang X; Guo Z; Gao Y; Zhao B; Liu X; Chen L; Qiao J; Yu C; Wang L; Li Y; Yu L
Front Immunol; 2024; 15():1325860. PubMed ID: 38487523
[TBL] [Abstract] [Full Text] [Related]
4. Mesothelin car T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV
Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682
[TBL] [Abstract] [Full Text] [Related]
5. New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo.
Jancewicz I; Śmiech M; Winiarska M; Zagozdzon R; Wisniewski P
Cancer Immunol Immunother; 2024 Jan; 73(2):30. PubMed ID: 38279989
[TBL] [Abstract] [Full Text] [Related]
6. Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host.
Zhou R; Wu ST; Yazdanifar M; Williams C; Sanders A; Brouwer C; Maher J; Mukherjee P
J Immunother; 2024 Apr; 47(3):77-88. PubMed ID: 38270462
[TBL] [Abstract] [Full Text] [Related]
7. Immunotherapy for Ovarian cancer: Disappointing or Promising?
Deng M; Tang F; Chang X; Liu P; Ji X; Hao M; Wang Y; Yang R; Ma Q; Zhang Y; Miao J
Mol Pharm; 2024 Feb; 21(2):454-466. PubMed ID: 38232985
[TBL] [Abstract] [Full Text] [Related]
8. Using Oncolytic Virus to Retask CD19-Chimeric Antigen Receptor T Cells for treatment of Pancreatic cancer: Toward a Universal Chimeric Antigen Receptor T-Cell Strategy for Solid Tumor.
Chen C; Park AK; Monroy I; Ren Y; Kim SI; Chaurasiya S; Priceman SJ; Fong Y
J Am Coll Surg; 2024 Apr; 238(4):436-447. PubMed ID: 38214445
[TBL] [Abstract] [Full Text] [Related]
9. Chimeric Antigen Receptor T Cell Therapy for Pancreatic cancer: A Review of Current Evidence.
Czaplicka A; Lachota M; Pączek L; Zagożdżon R; Kaleta B
Cells; 2024 Jan; 13(1):. PubMed ID: 38201305
[TBL] [Abstract] [Full Text] [Related]
10. car-T cell immunotherapy for ovarian cancer: hushing the silent killer.
Nasiri F; Farrokhi K; Safarzadeh Kozani P; Mahboubi Kancha M; Dashti Shokoohi S; Safarzadeh Kozani P
Front Immunol; 2023; 14():1302307. PubMed ID: 38146364
[TBL] [Abstract] [Full Text] [Related]
11. [Killing effect of anti-MSLN-icar-NK cells derived from induced pluripotent stem cells on ovarian epithelial cancer cells].
Fan RJ; Zhang YF; Wang YY; Wang Y; Zheng W
Zhonghua Fu Chan Ke Za Zhi; 2023 Dec; 58(12):922-929. PubMed ID: 38123198
[No Abstract] [Full Text] [Related]
12. Pyroptosis and the tumor immune microenvironment: A new battlefield in ovarian cancer treatment.
Wang A; Wang Y; Du C; Yang H; Wang Z; Jin C; Hamblin MR
Biochim Biophys Acta Rev Cancer; 2024 Mar; 1879(2):189058. PubMed ID: 38113952
[TBL] [Abstract] [Full Text] [Related]
13. Systemic inflammation adversely affects response to anamorelin in patients with pancreatic cancer.
Tsunematsu M; Uwagawa T; Onda S; Shirai Y; Okui N; Matsumoto M; Furukawa K; Haruki K; Ishizaki S; Ikegami T
Support Care Cancer; 2023 Nov; 31(12):732. PubMed ID: 38055066
[TBL] [Abstract] [Full Text] [Related]
14. Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and car/IL-15 engineering.
Lee D; Dunn ZS; Guo W; Rosenthal CJ; Penn NE; Yu Y; Zhou K; Li Z; Ma F; Li M; Song TC; Cen X; Li YR; Zhou JJ; Pellegrini M; Wang P; Yang L
Nat Commun; 2023 Nov; 14(1):6942. PubMed ID: 37938576
[TBL] [Abstract] [Full Text] [Related]
15. Natural killer cells for pancreatic cancer immunotherapy: Role of nanoparticles.
Kumar V; Mahato RI
Cancer Lett; 2023 Nov; 579():216462. PubMed ID: 37924937
[TBL] [Abstract] [Full Text] [Related]
16. Engineering strategies to optimise adoptive cell therapy in ovarian cancer.
Guerra C; Kalaitsidou M; Kueberuwa G; Hawkins R; Edmondson R
Cancer Treat Rev; 2023 Dec; 121():102632. PubMed ID: 37837788
[TBL] [Abstract] [Full Text] [Related]
17. Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression.
Jiang W; Gu G; Zhang Y; Song Y; Shi M; Wang G; Li H; Tao T; Qin J; Li X; Jia H; Jiao F; Xu W; Huang X
Pharmacol Res; 2023 Nov; 197():106942. PubMed ID: 37775021
[TBL] [Abstract] [Full Text] [Related]
18. Nanoscale car Organization at the Immune Synapse Correlates with car-T Effector Functions.
Sajman J; Yakovian O; Unger Deshet N; Almog S; Horn G; Waks T; Globerson Levin A; Sherman E
Cells; 2023 Sep; 12(18):. PubMed ID: 37759484
[TBL] [Abstract] [Full Text] [Related]
19. "Hurdles race for car T-cell therapy in digestive tract cancer".
Kronig MN; Wehrli M; Salas-Benito D; Maus MV
Immunol Rev; 2023 Nov; 320(1):100-119. PubMed ID: 37694970
[TBL] [Abstract] [Full Text] [Related]
20. Ligand-based adoptive T cell targeting CA125 in ovarian cancer.
Zhao H; Wu L; Dai J; Sun K; Zi Z; Guan J; Zhang L
J Transl Med; 2023 Sep; 21(1):596. PubMed ID: 37670338
[TBL] [Abstract] [Full Text] [Related]
[Next]
